Illumina s 2000 Revenue Crosses $1M Mark | GenomeWeb

NEW YORK, Jan 30 – Illumina said Tuesday its revenue crossed the $1 million mark in 2000, but expenses rocketed as the company stepped up R&D spending.

For the year, publicly traded Illumina, a maker of microarray technologies, posted revenues of $1.3 million, compared with $474,000 in 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.